Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Champlin

Showing results (261-270 of 279) with videos related to

Pageof 28
Sort By:
Blood|January 1, 1981
Prevention of graft rejection following bone marrow transplantationR P Gale, W Ho, S Feig, et al.
Blood|August 10, 1999
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantationD Przepiorka, T L Smith, J Folloder, et al.
American Journal of Hematology|July 10, 2001
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemiaS Bibawi, D Abi-Said, L Fayad, et al.
Bone Marrow Transplantation|October 12, 1999
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantationD Przepiorka, I Khouri, C Ippoliti, et al.
Bone Marrow Transplantation|November 1, 1996
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donorsM Körbling, K W Chan, P Anderlini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphomaD Przepiorka, K van Besien, I Khouri, et al.
Blood|June 15, 1997
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapyS Giralt, E Estey, M Albitar, et al.
Blood|February 7, 2001
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationS Giralt, P F Thall, I Khouri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcomeU Popat, D Przepiork, R Champlin, et al.
The American Journal of Medicine|March 1, 1996
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histologyK W van Besien, R C Mehra, S A Giralt, et al.
Pageof 28

Showing results (261-270 of 279) with videos related to

Sort By:
Pageof 28
Blood|January 1, 1981
Prevention of graft rejection following bone marrow transplantationR P Gale, W Ho, S Feig, et al.
Blood|August 10, 1999
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantationD Przepiorka, T L Smith, J Folloder, et al.
American Journal of Hematology|July 10, 2001
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemiaS Bibawi, D Abi-Said, L Fayad, et al.
Bone Marrow Transplantation|October 12, 1999
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantationD Przepiorka, I Khouri, C Ippoliti, et al.
Bone Marrow Transplantation|November 1, 1996
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donorsM Körbling, K W Chan, P Anderlini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphomaD Przepiorka, K van Besien, I Khouri, et al.
Blood|June 15, 1997
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapyS Giralt, E Estey, M Albitar, et al.
Blood|February 7, 2001
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationS Giralt, P F Thall, I Khouri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcomeU Popat, D Przepiork, R Champlin, et al.
The American Journal of Medicine|March 1, 1996
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histologyK W van Besien, R C Mehra, S A Giralt, et al.
Pageof 28